Skip to main content
. 2023 Jan 30;13(1):e066175. doi: 10.1136/bmjopen-2022-066175

Table 2.

Measures by time point assessed and mode of administration

Assessment goal Measure/study procedure Time point Mode
Diagnostic and screening Phone screen (to determine eligibility) Pre-B Interview
Screening, demographics, medical review B Self-report
Structured Clinical Interview for DSM-V B Interview
EEG B Clinician administered
SUD Timeline follow-back B, W, PT1 PT2 Interview
Alcohol Urge Questionnaire, Cocaine Urge Questionnaire or Opioid Urge Questionnaire B, W, PT1, PT2 Self-report
PTSD Clinician-Administered PTSD Scale B, PT1, PT2 Interview
PTSD Checklist for DSM-V B, PT1, PT2 Self-report
The Life Events Checklist B Self-report
Depression Inventory of Depressive Symptomatology Self-Report B, PT1, PT2 Self-report
Affect Positive and Negative Affect Schedule B, PT1, PT2 Self-report
Anxiety State-Trait Anxiety Inventory B, PT1, PT2 Self-report
Quality of Life Quality of Life Enjoyment and Satisfaction Questionnaire B, PT1, PT2 Self-report
Social and Occupational Functioning Assessment Scale B, PT1, PT2 Self-report
Sleep Pittsburgh Sleep Quality Index B, W, PT1, PT2 Self-report
General Clinical Global Impressions–Severity (CGI-s) B, PT1, PT2 Interview
CGI–Improvement (CGI-i) B, PT1, PT2 Interview
Treatment satisfaction Adapted Satisfaction with Treatment Form PT1, PT2 Self-report
Blinding questionnaire Treatment Blinding Questionnaire PT1 Self-report
Specimen collection Urine toxicology screen B, W, PT1, PT2 Laboratory
Blood draw B Laboratory
DNA collection B Laboratory

DSM-V, Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition; EEG, electroencephalography; PTSD, post-traumatic stress disorder; SUD, substance use disorder.